IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Novel EGFR TKIs for Advanced EGFR Mutant Advanced NSCLC
March 13, 2018 | Online


In patients with advanced EGFR mutant NSCLC, recent data shows that second generation EGFR TKI dacomitinib and third-line generation EGFR TKI osirmetinib have improved efficacy to first generation drugs such as gefitinib or erlotinib, These drugs have different toxicity profiles and penetration in the central nervous system. We will discuss clinical data and potential strategies to maximize benefit from these drugs in this group of patients.

Because of the limited penetration of first generation EGFR TKIs across the blood-brain barrier, radiotherapy has been considered the cornerstone of treatment of brain metastases. However the landscape is changing with the availability of third generation EGFR TKIs. We will discuss the clinical data available to date on the combination of EGFR TKIs and RT, the role of whole brain radiotherapy and future directions to improve outcomes within this group of patients.

Prof Corinne Faivre-Finn  FRCR MD PhD
Professor of Thoracic Radiation Oncology
Division of Molecular and 

Clinical Cancer Sciences


Raffaele Califano, MD
Consultant in Medical Oncology
The Christie NHS Foundation Trust

Manchester, UK